Welcome to our dedicated page for Assertio Holdings news (Ticker: ASRT), a resource for investors and traders seeking the latest updates and insights on Assertio Holdings stock.
Assertio Holdings, Inc. (NASDAQ: ASRT) generates a steady flow of news related to its role as a pharmaceutical company focused on oncology, neurology, and pain management. This news page aggregates company-issued press releases and other coverage so readers can follow developments that affect Assertio’s business and ASRT stock.
Recent communications emphasize Assertio’s commercial execution around Rolvedon, a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in certain adult cancer patients, and SYMPAZAN, an oral film formulation of clobazam approved for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. News items include clinical trial readouts, such as a phase 1 study of same-day dosing of Rolvedon with chemotherapy, and real-world evidence studies describing how Sympazan is used in daily clinical practice.
Investors and observers will also find updates on financial results, guidance ranges, and strategic priorities, including portfolio focus on core growth assets, responses to generic competition for products like Indocin, and steps to streamline the corporate structure. Assertio’s announcements cover quarterly net product sales, adjusted EBITDA, and commentary on commercial performance, alongside information about investor conference participation and earnings calls.
Governance and capital markets developments appear in the news flow as well, such as leadership transitions at the chief executive level, the appointment of a President and Chief Operating Officer, and the implementation of a 1-for-15 reverse stock split to support Nasdaq listing compliance. Subsequent confirmation from Nasdaq that Assertio regained compliance with listing requirements is also communicated through press releases.
By reviewing the ASRT news feed, readers can track clinical data publications, operational updates, executive changes, supply and licensing agreements, and listing status disclosures that help explain how Assertio is executing its stated strategy in oncology, neurology, and pain management.
Assertio Holdings reported Q3 2020 net product sales of $34.3 million, a 21.4% increase compared to the pro-forma Q2 2020. Non-GAAP sales were $33.7 million, maintaining consistency with the previous year despite COVID-19 disruptions. Demand for Zipsor increased by 25% quarter-over-quarter, while Indocin sales grew by 46% quarter-over-quarter. The company anticipates a 5% decline in full-year pro-forma revenue compared to 2019. Cash reserves declined to $34.7 million due to debt prepayments and restructuring costs. Assertio is focused on achieving $40 million in operational synergies from its merger.
Assertio Holdings, Inc. (Nasdaq: ASRT) will announce its Q3 2020 financial results on November 6, 2020. The management team will hold a live webcast at 8:30 a.m. ET to discuss the operating results and provide a business update. Assertio focuses on commercial pharmaceutical products in neurology, hospital, and pain management sectors. The company's growth strategy includes mergers and acquisitions, as well as licensing agreements. For more details, visit Assertio's website.
Assertio Holdings, Inc. (Nasdaq: ASRT) announced participation in the Cantor Virtual Global Healthcare Conference on September 16, 2020, at 2:00 pm ET. CEO Todd Smith will discuss Zyla Life Sciences integration, business strategy, financial results, and growth trends for the next year. The conference runs from September 15-17, 2020. Interested parties can find more details and listen to the webcast on Assertio's investor page. Assertio aims to be a leader in the pharmaceutical market, focusing on neurology, hospital, and pain management products.
Assertio Holdings reported its Q2 2020 financial results, highlighting a pro forma net product sales increase to $27.7 million compared to the previous quarter. The company successfully completed its merger with Zyla Life Sciences and fully integrated operations by the end of Q2. Assertio repaid $10 million of Senior Secured Notes ahead of schedule and projected mid-to-high single-digit growth for 2020. The cash position improved by over 40%, totaling $59.4 million at quarter-end, with a projected EBITDA margin exceeding 25%.
Assertio Holdings, Inc. (Nasdaq: ASRT) will release its Q2 2020 financial results on August 7, 2020. Following the announcement, management will host a live webcast at 8:30 a.m. ET to discuss the financials and provide a general business update. The webcast will be accessible on their investor relations website. Assertio focuses on bringing differentiated products to patients, with a strong portfolio in neurology, hospital care, and pain management.